News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioChemics, Inc. Announces Expanded Scope of Collaboration with a Leading Light Based Technology Company


6/3/2009 8:59:23 AM

DANVERS, Mass.--(BUSINESS WIRE)--BioChemics, Inc. (BCI), a company “enhancing drug delivery through biophysical modulation,” is pleased to announce that it has expanded the scope of its research collaboration agreement with Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer of light-based aesthetic treatment systems. The expanded scope of the agreement is to evaluate the use of BCI's VALE® based technology in conjunction with light based aesthetic treatments. BioChemics is a specialty pharmaceutical company that has developed a novel, transdermal drug delivery system called VALE® (Vaso-active Lipid Encapsulated), that allows a wide variety of actives to be delivered into the skin.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES